Pharma/fine chemicals roundup—17 September 2013
3:49 AM MDT | September 17, 2013 | By DEEPTI RAMESH
ICIG to acquire peptide APIs firm Peptisyntha from Solvay
International Chemical Investors Group (ICIG), a privately owned industrial holding company, says that it has entered into an agreement with Solvay to acquire the latter's subsidiary Peptisyntha (Brussels), a custom manufacturer of peptides for pharmaceutical use. Financial details of the deal have not been disclosed. The transaction is expected to be completed this fall, and Peptisyntha will become a member of ICIG's CordenPharma platform as its third site offering peptides manufacturing. For Solvay, the divestiture marks another step in focusing on its core industrial activities and completes the group's exit from life science activities. Peptisyntha is a leading manufacturer of peptide active pharmaceutical ingredients (APIs) and peptidomimetics.
ScinoPharm signs API manufacturing deal with US firm
ScinoPharm Taiwan (Shanhua, Taiwan) says that its manufacturing facility at Tainan, Taiwan will commercially manufacture topiramate active pharmaceutical ingredient (API) for Trokendi XR, a novel once-daily extended release formulation of topiramate for the treatment of epilepsy that was developed and recently launched by Supernus Pharmaceuticals (Rockville, MD) in the US market. Supernus received approval last month from the US FDA to market Trokendi XR.
Aurobindo to acquire Hyacinths Pharma as part of APIs push
Aurobindo Pharma (Hyderabad, India) says it will acquire, from existing private shareholders, Hyacinths Pharma (Andhra Pradesh, India), a company incorporated to manufacture active pharmaceutical ingredients (APIs). Hyacinths, located near Aurobindo’s operations, has a 53-acre site at Srikakulum, India—also near Aurobindo—and all the necessary approvals to begin production of APIs. The acquisition forms part of Aurobindo’s previously announced plan to raise sales of APIs to $700 million by fiscal 2016. In fiscal 2013, the company's APIs sales were $465 million.
FDA issues import alert against Ranbaxy plant
The US Food and Drug Administration (FDA) issued an import alert on 16 September for a Ranbaxy Laboratories (Gurgaon, India) facility at Mohali, India, for violating US drug manufacturing requirements, known as current good manufacturing practices (cGMP). Under the alert, US officials may detain at the US border drug products manufactured at the Mohali facility and the company will remain on the import alert until it complies with cGMP, FDA says. FDA says it does not anticipate that this action will cause a supply disruption or shortage of drugs in the United States.
VCI sees German output gains on strength in fine and specialty chemicals
Industry association VCI (Frankfurt) says it continues to forecast an increase in German chemical production of 1.5% for the full-year 2013, driven by gains in fine and specialty production. Chemical sales are expected to rise by 1%, to €189 billion ($249 billion). Producer prices are expected to fall by about 0.5%, VCI says. VCI had previously forecast stagnation in prices for 2013. Second-quarter production of chemicals rose 2.6% in comparison with second-quarter 2012, driven by pharmaceuticals, VCI says.
Aceto earnings rise on strong pharma business
Aceto’s (Port Washington, NY) fiscal fourth-quarter net income was up 35.7% year-on-year (YOY), to $5.4 million, on sales up 11%, to $123.1 million. Adjusted net income totaled $5.6 million. Aceto’s fiscal fourth-quarter ended on 30 June. Sales increased in the company’s human health business, on new generic product launches and higher sales of nutritional supplements. Performance chemicals and pharmaceutical ingredients revenue growth was “modest,” however, the company says. Aceto does not disclose segment sales figures.
Connect with IHS Chemical Week
Our related sites